

Policy: MPA G2113

Section: Medical Policy

Subject: Oral Cancer Screening and Testing

Applicable Lines of Business

Commercial	x	CHIP	x
Medicare	x	ACA	x
Medicaid	x		

I. Policy: Oral Cancer Screening and Testing

II. Purpose/Objective: To provide a policy of coverage regarding

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children’s Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

Oral Cancer Screening and Testing

Policy Number: AHS – G2113 – Oral Cancer Screening and Testing

Original Effective Date: 06/01/2022
Current Effective Date: 02/01/2026

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

Policy Description

Oral cancer is defined as cancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one third of the tongue. Squamous cell carcinoma is the most common type of oral cancer.¹

Related Policies

Policy Number	Policy Title
N/A	Not Applicable

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node, testing for high-risk HPV with

either mRNA expression testing for HPV E6/E7 or immunohistochemistry for p16 expression **MEETS COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

2) To screen, detect, or diagnose oral cancer, the following testing **DOES NOT MEET COVERAGE CRITERIA**:

- a) Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites).
- b) Genotyping of HPV (e.g., OraRisk® HPV).
- c) Gene expression profiling.
- d) Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™).
- e) Detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test).

Table of Terminology

Term	Definition
8-OHdG	8-hydroxy-2'-deoxyguanosine
ACS	American Cancer Society
ADA	American Dental Association
AF	Autofluorescence
AHSG	Alpha-2-HS-glycoprotein
ASCO	American Society of Clinical Oncology
AUC	Area under curve
AZGP1	Zinc-alpha-2-glycoprotein
BPIFB2	Bactericidal/permeability-increasing protein fold containing family B member 2
CAP	College of American Pathologists
CD59	Cluster of differentiation 59
CDC	Centers for Disease Control and Prevention
CL	Chemiluminescence
CLIA '88	Clinical Laboratory Improvement Amendments of 1988
CMS	Centers for Medicare and Medicaid
COE	Conventional oral examination
CPT	Current procedural terminology
DNA	Deoxyribonucleic acid
<i>DUSP1</i>	<i>Dual specificity phosphatase 1</i>
EBER	Epstein-Barr-encoded ribonucleic acid
EBV	Epstein-Barr virus
EHNS	European Head and Neck Society
ESMO	European Society for Medical Oncology
ESTRO	European Society for Radiotherapy and Oncology
<i>H3F3A</i>	<i>H3 histone, family 3A</i>
HNSCC	Head and neck squamous cell carcinoma
HPV	Human papillomavirus
HR	High-risk
HR-HPV	High-risk human papillomavirus infection

IHC	Immunohistochemistry
<i>IL-8</i>	<i>Interleukin-8</i>
<i>IL-1B</i>	<i>Interleukin-1B</i>
KLK1	Kallikrein 1
KRT6C	Keratin 6C
LACRT	Lacritin
LBDS	Light-based detection systems
LC-MS	Light chromatography-mass spectrometry
LDT	Laboratory-developed test
LED	Light emitting diodes
M2BP	Mac-2 binding protein
MDA	Malondialdehyde
<i>MED15</i>	<i>Mediator complex subunit 15</i>
miRNA	Micro ribonucleic acid
mRNA	Messenger ribonucleic acid
MRP14	Migration inhibitory factor-related protein 14
MSP	Methylation-specific polymerase chain reaction
NCCN	National Comprehensive Cancer Network
<i>OAZ1</i>	<i>Ornithine decarboxylase antizyme 1</i>
OC	Oral cancer
OPC	Oropharyngeal cancer
OPMD	Oral potentially malignant disorders
OSCC	Oral squamous cell carcinoma
<i>PCQAP</i>	<i>Mediator complex subunit 15</i>
PMD	Potentially malignant disorder
<i>RASSF1A</i>	<i>Ras association domain family 1 isoform A (gene)</i>
RASSF1 α	Ras association domain family 1 isoform A (protein)
RNA	Ribonucleic acid
<i>S100P</i>	<i>S100 Calcium Binding Protein P</i>
<i>SAT</i>	<i>Spermidine/spermine N1-acetyltransferase</i>
SCC	Squamous cell carcinoma
SCCUP	Squamous cell carcinoma of unknown primary
<i>TIMP3</i>	<i>TIMP metalloproteinase inhibitor 3</i>
USPSTF	United States Preventive Services Task Force

Scientific Background

The American Cancer Society (ACS) estimates the 2019 incidence of oral cancer to be 53,000 cases with approximately 10,860 deaths.² The American Cancer Society estimates that in the United States in 2024, approximately 59,660 people will be diagnosed with oral cavity and oropharyngeal cancers and approximately 12,770 people will die from these cancers.³ Oral squamous cell carcinoma (OSCC) is the most common form of oral cavity cancer, which constitutes 94.08% of all epithelial tumors and 80.05% of all oral cancers.^{4,5} Many cases are preceded by a potentially malignant disorder (PMD), which is a heterogeneous group of conditions including erythroplakia, non-homogeneous leukoplakia, erosive lichen planus, oral submucous fibrosis and actinic keratosis.⁶ The early detection and excision of PMD can prevent malignant transformation.⁶⁻⁸

Human papillomavirus (HPV) is a common sexually transmitted infection that may lead to the development of warts or cancer in various parts of the body including the back of the throat, tonsils, and base of the tongue. This

type of cancer is known as oropharyngeal cancer. HPV is also a major contributor to the development of head and neck squamous cell carcinoma (HNSCC), which can develop in the mouth, nose, and throat.⁹ According to the CDC (2025), there is no test to determine an individual's HPV status, and "there is no approved HPV test to find HPV in the mouth or throat."

Diagnosing and treating dermatologic lesions of the mouth and gums is challenging for most clinicians because of the wide variety of disease processes that can present with similar appearing lesions and the fact that most clinicians receive inadequate training in mouth diseases.¹¹ Several index tests have been proposed as adjuncts to a conventional oral examination (COE) to improve diagnostic test accuracy.¹²⁻¹⁶ These tests include vital staining, brush cytology, and blood or saliva analysis. These screening tests are not only used for diagnostic purposes but can also be utilized as a tool to measure any changes that may be signs of future disease development.¹⁷

Additionally, blood or saliva can be tested for biomarkers for cancer. The tests are non-invasive but have low standardization and are not widely used in clinical practice.¹⁸ Nonetheless, saliva has been identified as an ideal diagnostic medium for the early detection of HNSCC activity because it is close to the tumor site and is an easy sample to obtain.¹⁹ Macey, et al. (2015) concluded that none of the adjunctive biomarker tests can be recommended as a replacement for the currently used standard of COE followed by a scalpel biopsy and histological assessment. However, the NCCN has stated that that "Expression of p16 as detected by IHC [immunohistochemistry] is a widely available surrogate biomarker that has a very good agreement with HPV status as determined by the gold standard of HPV E6/E7 mRNA expression."²⁰ The protein known as p16 slows cell division, therefore acting as a tumor suppressor. Researchers have identified *p16^{INK4a}*, *RASSF1A*, *TIMP3*, and *PCQAP/MED15* as tumor suppressor genes that exhibited "excellent diagnostic accuracy in the early detection of OC [oral cancer] at 91.7% sensitivity and 92.3% specificity and of OPC [oropharyngeal cancer] at 99.8% sensitivity and 92.1% specificity from healthy controls."²¹ A review by Kaur, et al. (2018) that researched salivary biomarkers for oral cancer and pre-cancer screening have identified a plethora of salivary biomarkers which showed an improvement in oral cancer diagnoses including mRNAs, salivary transcriptomes (*IL-8*, *IL-1B*, *DUSP1*, *H3F3A*, *OAZ1*, *S100P*, and *SAT* were highly specific (91%) and sensitive (91%) for oral cancer detection), and salivary biomarkers (M2BP, profilin, CD59, MRP14, and catalase had a sensitivity of 83% and a specificity of 90% for oral cancer detection).²²

The OraRisk® HPV by OralDNA Labs is a salivary diagnostic test that analyzes the molecular genotypes of HPV. The test can identify a total of 51 types of oral HPV including high-risk, low-risk and unknown-risk genotypes. High-Risk Genotypes: 16, 18, 26, 30, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82. Low-Risk Genotypes: 2a, 6, 11, 32, 40, 42, 43, 44, 54, 55, 57, 61, 62, 71, 72, 74, 77, 81, 83, 84, 89. Unknown-Risk Genotypes: 41, 49, 60, 75, 76, 80, 85.²³

Omnipathology offers a non-invasive screening test for detecting high-risk HPV DNA (14 high-risk HPV types) in the oropharynx (i.e., the tonsils and base of the tongue). The test is collected via oropharyngeal swab with no biopsy or tissue sample required. The test does not depend on clinical signs or symptoms of a confirmed tumor, as it is designed to screen asymptomatic individuals who may be at risk for oropharyngeal HPV infection.²⁴ Routine swab screening in asymptomatic individuals is not recommended in the latest cancer guidelines, including the CAP 2025 guideline, which does not recommend routine screening for oropharyngeal squamous cell carcinoma (OPSCC) or HPV-associated head and neck cancers in asymptomatic individuals. All endorsed testing by CAP and other guidelines is based on one or more of the following: confirmed or suspected tumor via imaging or biopsy; diagnostic workup of nodal metastases; histological evidence; and specific staging, prognostic, or therapeutic decisions.²⁵

Clinical Utility and Validity

Nagi, et al. (2016) conducted a systematic review to evaluate the effectiveness of adjunctive devices that utilize the principles of chemiluminescence and tissue autofluorescence in the detection of OSCC and oral potentially malignant disorders (OPMD). Twenty primary studies published satisfied the criteria for selection. Ten used

chemiluminescence and ten used tissue autofluorescence. ViziLite was used for evaluation of chemiluminescence, and it was evaluated at a sensitivity of 0.771 to 1.00 and specificity of 0.00 to 0.278. Tissue autofluorescence was evaluated with VELscope. This technique was evaluated at a sensitivity of 0.22-1.00 and specificity of 0.16 to 1.00. The authors concluded that more clinical trials in the future should be conducted to establish optical imaging as an efficacious adjunct tool in early diagnosis of OSCC and OPMD.²⁶

Shaw, et al. (2022) conducted a systematic review to compare the existing evidence on diagnostic accuracy of salivary biomarkers with their estimation method in detecting early OSCC. Salivary biomarkers provide promising complementary alternative diagnostic adjunct for its simple non-invasive collection and technique and to screen large population. “18 studies were included for qualitative synthesis, and out of that 13 for meta-analysis. Sensitivity and specificity were calculated with AUC. For mRNA it was 91% and 90% with 0.96 AUC, miRNA had 91% and 91% with 0.95 AUC for PCR. IL-1B had 46% and 60% with 0.61 AUC, S100p had 45% and 90% with 0.57 AUC for ELISA. IL-8 had 54% and 74% for ELISA and 89% and 90% for PCR with 0.79 AUC and DUSP1 had 32% and 87% for ELISA and 76% and 83% for PCR with 0.83 AUC respectively. Early detection of OSCC was best achieved by screening for salivary mRNA and miRNA estimated by PCR.”²⁷

Lingen, et al. (2017) performed a meta-analysis of the screening adjuncts for oral cancer. The authors evaluated cytologic adjuncts as well as vital staining, tissue reflectance, autofluorescence, and salivary biomarkers. The vital staining cohort included 15 studies with 1453 lesions and was evaluated at a 0.87 sensitivity and 0.71 specificity. The tissue reflectance cohort (5 studies, 390 lesions) was assessed at a 0.72 sensitivity and 0.31 specificity. The autofluorescence segment (7 studies, 616 lesions) was computed at a 0.90 sensitivity and a 0.72 specificity. The authors stated, most biomarkers showed a wide range of diagnostic test accuracy results, “with sensitivity ranging from 0.5 to 0.9 and specificity ranging from 0.63 to 0.9.” Finally, cytology (15 studies, 2148 lesions) was assessed at a 0.92 sensitivity and 0.94 specificity. The authors concluded that cytology appeared to be most accurate adjunct.²⁸

Another systematic review was completed that focused on the use of oral brush cytology for the early detection of oral cancer and OPMDs.²⁹ Thirty-six of the 343 abstracts and articles identified met the inclusion criteria, with publication dates ranging from 1994 to 2017. These articles led to the inclusion of 4302 total samples from OPMDs, OSCC, and healthy controls. The results were somewhat troubling. “Findings from this study indicate that meaningful evidence-based recommendations for the implementation of a minimally invasive technique to be utilized as an adjunctive tool for screening and early detection of oral cancer and OPMDs are complicated from the reported studies in the literature.”²⁹

Kaur, et al. (2018) completed a review which focused on salivary biomarkers for oral cancer and pre-cancer screening. A total of 270 articles published between 1995 and 2017 were identified for this review. The authors note that biomarkers may be arranged into four categories: normal health (*IL-8*, *IL-1β*, etc.), general health (glycolytic enzyme lactate dehydrogenase, etc.), specific (*S100P* mRNA for cancer), and non-specific salivary (8-OHdG and MDA biomarkers of oral cancer and pre-cancer).²² Results from this study led to the conclusion that “Biomarkers such as methylation markers, IL-8, actin, myosin, and miRNAs are very speculative and remain without sufficient scientific evidence when it comes to oral cancer and pre-cancer detection using body fluids. Salivary peptides such as protein 14, Mac-2 binding protein, profilin 1, CD59, defensin-1, catalase proteins, etc. with sensitivity approximating 90% and specificity 80% for oral cancer diagnosis have been described”; “Furthermore, five salivary metabolites such as valine, lactic acid, and phenylalanine in combination yielded satisfactory accuracy (0.89), sensitivity (94.6%), and specificity (84.4%) in distinguishing oral cancer from controls or oral pre-cancer, respectively.”²² Based on the results in this large group of studies, the researchers state that the “Combination approach of salivary biomarkers could be used as [a] screening tool to improve early detection and diagnostic precision of oral pre-cancer and cancer.”²² The findings of this extensive review highlight that it is important for researchers to mitigate the current challenges involved with the use of salivary biomarkers for oral cancer and pre-cancer screening as this technique has the potential to improve early detection and diagnostic methods.

Using “targeted proteomics, identified initially by relative quantification of salivary proteins on LC-MS [light chromatography-mass spectrometry],” Jain, et al. (2021) identified a potential salivary biomarker panel having been motivated by the high prevalence, incidence, and mortality of oral cancer/OSCC among Indians. In a case-control cohort study, “Out of the twelve proteins validated, two proteins AHSG and KRT6C were significantly upregulated and four proteins, AZGP1, KLK1, BPIFB2 and LACRT were found to be significantly downregulated,” but when accounting for tobacco consumption habits, “AHSG and AZGP1 were dysregulated in cases compared to controls irrespective of their tobacco consumption habits. While KRT6C, KLK1 and BPIFB2 were significantly dysregulated only in the cases having tobacco consumption habits.” AZGP1 is important in insulin sensitivity and the cell cycle; KLK1 is a serine protease involved in “remodelling of the extracellular matrix, cellular proliferation and differentiation, angiogenesis, and apoptosis;” BPIFB2 is a lipid transfer/lipopolysaccharide binding protein that is not well understood in cancer; KRT6C is a type II keratin subtype and is expressed in “filiform papillae of the tongue, stratified epithelial lining of the oesophagus, and oral mucosa and in glandular epithelia;” and AHSG is involved in “multiorgan expression during embryogenesis,” but is mostly in the liver and some osteoblasts in adults. In their risk prediction model, AZGP1, AHSG, and KRT6C had sensitivities of 82.4%, 78%, and 73.5%, respectively for all stages of OSCC, and 87.9%, 87.5%, and 73.5%, respectively for late stage OSCC.³⁰

Lim, et al. (2016) completed a study to determine the diagnostic ability of four HNSCC biomarkers (RASSF1 α , p16^{INK4a}, TIMP3, PCQAP/MED15) isolated from saliva. The DNA methylation status of these biomarkers was measured via methylation-specific PCR (MSP). Data from a total of 88 HNSCC patients and 122 healthy controls was analyzed. The authors found that a “salivary DNA tumour-suppressor methylation gene panel has the potential to detect early-stage tumours in HPV-negative HNSCC patients. HPV infection was found to deregulate the methylation levels in HPV-positive HNSCC patients”; biomarker analysis of HPV-negative HNSCC patients compared to healthy controls generated a sensitivity of 71% and specificity of 80%, while biomarker analysis of HPV-positive HNSCC patients compared to healthy controls generated a sensitivity of 80% and a specificity of 74%.¹⁹

In their overview of non-invasive diagnostic devices in oral oncology, Mascitti, et al. (2018) discussed and reviewed the Vizilite® chemiluminescence-based detected device for PMD and OSCC (Zila Pharmaceuticals), VELscope® non-magnifying device for visualization of oral mucosa autofluorescence (LED Medical Diagnostics), Identafi® device for multispectral screening of PMD (StarDental-DentalEZ), Microlux/DL™ chemiluminescence-based device (AdDent Inc.), GOCCLES® device for autofluorescence abnormalities in the oral cavity (Pierrel S.p.A), Orasoptic DK™ chemiluminescence-based device (Orasoptic), and other autofluorescence-based devices like those from Sapphire® PLUS LD (DenMat Holdings), DentLight DOE™ Oral Exam System (DentLight), and ORalID™ 2.0 (Forward Science Technologies). Ultimately, they concluded that there would be “great potential for screening and monitoring lesions. Unfortunately, to date several factors hinder an extensive use of these devices: (1) data do not demonstrate clear superiority of these methods compared to COE; (2) there remains the need for well-designed multicentre prospective studies; (3) these devices exhibit a not negligible interobserver variability limiting their use to clinicians with significant experience in oral pathology.” However, in terms of their benefits, “the current evidence suggests that these devices: (1) seem to be useful in assessing lesion margins that must be biopsied and, therefore, may be useful in surgical management; (2) can be used to investigate biological aspects of oral carcinogenesis, leading to more accurate methods for interpreting data from LBDS [light-based detection systems]; (3) can be enhanced with new approaches used to analyse optical imaging data, with the aim to quantify the results obtained; (4) lowering the costs of these devices could indirectly lead to greater attention for oral lesions among both patients and general dental practitioners, allowing in turn to promote a culture of oral cancer prevention; (5) finally, the possibility of implementing LBDS through the use of tissue-marking dyes can in principle allow to develop strategies for the use of nanoparticles. Indeed, nanoparticles can provide molecular targeted imaging, with higher image contrast and resolution.”³¹

Ribeiro, et al. (2021) conducted a study aiming to identify prognostic biomarkers for OSCC using a whole genome technology and evaluate their clinical utility. With using array comparative genomic hybridization

technology from 62 patients with OSCC, they found that the “chromosomes most commonly altered were 3p, 3q, 5q, 6p, 7q, 8p, 8q, 11q, 15q, 17q, and 18q,” with a greater frequency of alterations found on 3p, 3q, 8p, 8q, and 11q. To differentiate between patients with and without metastases or relapses after primary treatment, the researchers identified a genomic signature of genes including *OC LN*, *CLDN16*, *SCRIB*, *IKBKB*, *PAK2*, *PIK3CB*, and *YWHAZ*; this rendered an overall accuracy of 79%. An amplification of the *PIK3CB* gene also predicted metastases and relapses in addition to reducing median survival by more than five years. This demonstrated the potential use of genes in developing precision medicine and treating patients with OSCC.³²

Guidelines and Recommendations

US Preventive Services Task Force (USPSTF)

In 2013, the USPSTF published final recommendations for screening of oral cancer. The recommendation stated that “the current evidence is insufficient to assess the balance of benefits and harms of screening for oral cancer in asymptomatic adults.” The USPSTF also noted that “although there is interest in screening for oral HPV infection, medical and dental organizations do not recommend it.”³³

National Comprehensive Cancer Network (NCCN)

The NCCN clinical practice guidelines on head and neck cancers does not mention the use of adjunctive screening aids based on autofluorescence or tissue reflectance as a management tool.²⁰ Regarding HPV, the NCCN states that “There are currently no diagnostic tests with regulatory approval.”²⁰ The NCCN recommends “evaluation of tumor HPV status by use of a surrogate of p16 IHC in all patients diagnosed with an oropharyngeal cancer. Expression of p16 as detected by IHC [immunohistochemistry] is a widely available surrogate biomarker that has very good agreement with HPV status as determined by HPV E6/E7 mRNA expression.”²⁰

Additionally, the NCCN states “The performance of various plasma cell-free HPV DNA detection assays (preferably validated per CLIA and CAP regulatory guidelines) for a diagnosis of HPV-positive oropharyngeal cancer against a gold standard of E6/E7 mRNA detection is unknown.”²⁰

College of American Pathologists (CAP)

The CAP published guidelines on human papillomavirus testing in head and neck carcinomas. These guidelines state that “For oropharyngeal tissue specimens (ie, noncytology), pathologists should perform HR-HPV [high-risk HPV] testing by surrogate marker p16 IHC.”³⁴

The CAP updated their guidelines on HPV testing in head and neck carcinomas in 2025, reaffirming the above statement as well as adding the following recommendations:

“In certain scenarios HPV-specific testing should be performed:

- a) in geographic regions with a low prevalence of HR-HPV-associated OPSCC;
- b) when p16 immunostaining is equivocal (50%-70% staining or when staining is extensive but weak);
- c) when there is a discrepancy between p16 staining and morphology;
- d) for large, multisite tumors overlapping the oropharynx;
- e) when specimens are from a non-tonsillar, non-base of tongue oropharyngeal site; and
- f) when required by clinical trials.”²⁵

The CAP recommends that pathologists perform high-risk HPV (HR-HPV) testing on all patients with newly diagnosed OPSCC (strong recommendation, evidence level high), sinonasal squamous cell carcinoma (SCC) (conditional recommendation, evidence level moderate), and metastatic SCC of unknown primary in a cervical lymph node (strong recommendation, evidence level high). The CAP advises against routine HR-HPV testing in patients with non-squamous carcinomas of the head and neck for prognostic purposes (strong recommendation, evidence level high).²⁵

American Society of Clinical Oncology (ASCO)

An expert panel from the ASCO has “determined that the recommendations from the HPV Testing in Head and Neck Carcinomas guideline, published in 2018, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the [CAP] guideline and added minor qualifying statements.”³⁵

The ASCO states that “It is recommended that HPV tumor status should be determined for newly diagnosed oropharyngeal squamous cell carcinomas. HPV tumor status testing may be performed by surrogate marker p16 immunohistochemistry either on the primary tumor or from cervical nodal metastases only if an oropharyngeal primary tumor is present.”³⁵

Regarding diagnosis and management of squamous cell carcinoma of unknown primary (SCCUP) in the head and neck, the ASCO states with a moderate strength recommendation, “High-risk [HPV] human papillomavirus (HPV) testing should be done routinely on level II and III SCCUP nodes. Epstein-Barr virus (EBV) testing should be considered on HPV-negative metastases... HR-HPV testing may be done nonroutinely for SCC metastases at other nodal levels when the clinical suspicion is high.”³⁶

European Head and Neck Society (EHNS)-European Society for Medical Oncology (ESMO)-European Society for Radiotherapy and Oncology (ESTRO)

In 2020, the EHNS, ESMO, and ESTRO released joint clinical practice guidelines for SCC of the oral cavity, larynx, oropharynx, and hypopharynx. For HPV testing, they recommended that “for SCCHN of unknown primary, p16 and EBER [Epstein-Barr-encoded RNA] are recommended. If p16 staining is positive, another specific HPV test should be carried out to confirm the HPV status [III, A].” p16 measured by immunohistochemistry is validated in use as a surrogate marker for HPV-induced oropharyngeal cancer and prognostic factor for oropharyngeal cancer [I, A].³⁷

Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, please visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81599	Unlisted multianalyte assay with algorithmic analysis
82397	Chemiluminescent assay
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed

CPT	Code Description
87626	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (e.g., 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (e.g., human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy Proprietary test: mRNA CancerDetect™ Lab/Manufacturer: Viome Life Sciences, Inc
0429U	Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Proprietary test: Omnipathology Oropharyngeal HPV PCR Test Lab/Manufacturer: OmniPathology Solutions, Medical Corporation

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Evidence-based Scientific References

- Gross N, Lee N, Okuno S, Rao S. Treatment of stage I and II (early) head and neck cancer: The oral cavity. Updated April 11, 2025. <https://www.uptodate.com/contents/treatment-of-stage-i-and-ii-early-head-and-neck-cancer-the-oral-cavity>
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*. 2019;69(1):7-34. doi:10.3322/caac.21551
- ACS. Key Statistics for Oral Cavity and Oropharyngeal Cancers. <https://www.cancer.org/cancer/oral-cavity-and-oropharyngeal-cancer/about/key-statistics.html>
- Scully C, Porter S. ABC of oral health. Oral cancer. *BMJ (Clinical research ed)*. 2000;321(7253):97-100.
- Dhanuthai K, Rojanawatsirivej S, Thosaporn W, et al. Oral cancer: A multicenter study. *Med Oral Patol Oral Cir Bucal*. 2018;23(1):e23-e29. doi:10.4317/medoral.21999
- Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2007;36(10):575-80. doi:10.1111/j.1600-0714.2007.00582.x
- Brocklehurst P, Kujan O, O'Malley L, Ogden GR, Shepherd S, Glenny AM. Screening programmes for the early detection and prevention of oral cancer. *Cochrane Database of Systematic Reviews*. 2013;(11)doi:10.1002/14651858.CD004150.pub4
- van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral oncology*. 2009;45(4-5):317-23. doi:10.1016/j.oraloncology.2008.05.016
- Borsetto D, Cheng J, Payne K, et al. Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers. *Crit Rev Oncog*. 2018;23(3-4):235-245. doi:10.1615/CritRevOncog.2018027689
- CDC. About Genital HPV Infection. <https://www.cdc.gov/sti/about/about-genital-hpv-infection.html>
- Lodi G. Oral Lesions. <https://www.uptodate.com/contents/oral-lesions>

12. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. *Oral oncology*. 2008;44(1):10-22. doi:10.1016/j.oraloncology.2007.06.011
13. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. *Journal of the American Dental Association (1939)*. 2008;139(7):896-905; quiz 993-4.
14. Fedele S. Diagnostic aids in the screening of oral cancer. *Head & neck oncology*. 2009;1:5. doi:10.1186/1758-3284-1-5
15. Seoane Leston J, Diz Dios P. Diagnostic clinical aids in oral cancer. *Oral oncology*. 2010;46(6):418-22. doi:10.1016/j.oraloncology.2010.03.006
16. Rethman MP, Carpenter W, Cohen EE, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. *Journal of the American Dental Association (1939)*. 2010;141(5):509-20.
17. Speight PM, Epstein J, Kujan O, et al. Screening for oral cancer-a perspective from the Global Oral Cancer Forum. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2017;123(6):680-687. doi:10.1016/j.oooo.2016.08.021
18. Macey R, Walsh T, Brocklehurst P, et al. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. *The Cochrane database of systematic reviews*. 2015;(5):Cd010276. doi:10.1002/14651858.CD010276.pub2
19. Lim Y, Wan Y, Vagenas D, et al. Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. *BMC Cancer*. 2016;16(1):749. doi:10.1186/s12885-016-2785-0
20. NCCN. NCCN Clinical Practice Guidelines in Oncology - Head and Neck Cancers Version 4.2025. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
21. Liyanage C, Wathupola A, Muraleetharan S, Perera K, Punyadeera C, Udagama P. Promoter Hypermethylation of Tumor-Suppressor Genes p16(INK4a), RASSF1A, TIMP3, and PCQAP/MED15 in Salivary DNA as a Quadruple Biomarker Panel for Early Detection of Oral and Oropharyngeal Cancers. *Biomolecules*. 2019;9(4)doi:10.3390/biom9040148
22. Kaur J, Jacobs R, Huang Y, Salvo N, Politis C. Salivary biomarkers for oral cancer and pre-cancer screening: a review. *Clin Oral Investig*. 2018;22(2):633-640. doi:10.1007/s00784-018-2337-x
23. OralDNA. OraRisk® HPV Complete Genotyping. <https://www.oraldna.com/test/ohpv-complete/>
24. Omnipathology. OROPHARYNGEAL HPV TESTING. 2025. <https://www.omnipathology.com/oral-hpv-testing>
25. Lewis JS, Jr, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline Update. *Archives of Pathology & Laboratory Medicine*. 2025;149(6):e115-e150. doi:10.5858/arpa.2024-0388-CP
26. Nagi R, Reddy-Kantharaj YB, Rakesh N, Janardhan-Reddy S, Sahu S. Efficacy of light based detection systems for early detection of oral cancer and oral potentially malignant disorders: Systematic review. *Med Oral Patol Oral Cir Bucal*. 2016;21(4):e447-55. doi:10.4317/medoral.21104
27. Shaw AK, Garcha V, Shetty V, et al. Diagnostic Accuracy of Salivary Biomarkers in Detecting Early Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. *Asian Pacific Journal of Cancer Prevention*. 2022;23(5):1483-1495. doi:10.31557/apjcp.2022.23.5.1483
28. Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. *The Journal of the American Dental Association*. 2017;148(10):712-727.e10. doi:10.1016/j.adaj.2017.07.032
29. Alsarraf AH, Kujan O, Farah CS. The utility of oral brush cytology in the early detection of oral cancer and oral potentially malignant disorders: A systematic review. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2018;47(2):104-116. doi:10.1111/jop.12660
30. Jain A, Kotimoole CN, Ghoshal S, et al. Identification of potential salivary biomarker panels for oral squamous cell carcinoma. *Scientific Reports*. 2021;11(1):3365. doi:10.1038/s41598-021-82635-0
31. Mascitti M, Orsini G, Tosco V, et al. An Overview on Current Non-invasive Diagnostic Devices in Oral Oncology. *Front Physiol*. 2018;9:1510-1510. doi:10.3389/fphys.2018.01510
32. Ribeiro IP, Esteves L, Santos A, et al. A seven-gene signature to predict the prognosis of oral squamous cell carcinoma. *Oncogene*. 2021;40(22):3859-3869. doi:10.1038/s41388-021-01806-5

33. Moyer VAobot, U. S. Preventive Services Task Force. Screening for Oral Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine*. 2014;160(1):55-60. doi:10.7326/M13-2568
34. Lewis JS, Jr., Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. *Arch Pathol Lab Med*. 2018;142(5):559-597. doi:10.5858/arpa.2017-0286-CP
35. Fakhry C, Lacchetti C, Rooper LM, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. *J Clin Oncol*. 2018;36(31):3152-3161. doi:10.1200/jco.18.00684
36. Maghami E, Ismaila N, Alvarez A, et al. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. *J Clin Oncol*. 2020;38(22):2570-2596. doi:10.1200/jco.20.00275
37. Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31(11):1462-1475. doi:10.1016/j.annonc.2020.07.011

Revision History

Effective Date	Summary
02/01/2026	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Added “or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node” to CC1, now reads: “1) To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node, testing for high-risk HPV with either mRNA expression testing for HPV E6/E7 or immunohistochemistry for p16 expression MEETS COVERAGE CRITERIA.”</p> <p>New CC2.e.: “e) Detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test).”</p> <p>Off-Cycle Coding Modification: Added CPT code 87626 (effective date 1/1/2025).</p> <p>Revised code description for CPT code 87624 (effective date 1/1/2025).</p>
01/01/2025	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>CC1 edited for clarity on the intent of this test (establishing HPV tumor status) for oropharyngeal cancer “1) To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV with either mRNA expression testing for HPV E6/E7 or immunohistochemistry for p16 expression MEETS COVERAGE CRITERIA.”</p> <p>Removed CPT code 87623</p> <p>Off-cycle coding modification: Added CPT 0429U (effective date 1/1/2024)</p>
11/03/2023	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Lesion identification systems are outside the scope of our enforcement, leading to edits to the body of the document, CC verbiage, and a title change to “Oral Cancer Screening and Testing”.</p>

	<p>CC1 edited for clarity. Former CC2 and CC3 were combined into a single CC, now reads: “2) To screen, detect, or diagnose oral cancer, the following testing DOES NOT MEET COVERAGE CRITERIA: a) Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites). b) Genotyping of HPV (e.g., OraRisk® HPV). c) Gene expression profiling. d) Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™).”</p>
12/01/2022	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following modification to coverage criteria: CC2b removed, as this test is no longer available: “MOP™ testing” Added PLA code 0296U.</p>
06/01/2022	Initial Policy Implementation

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD’s will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.